Pertinax's HCC candidate attracts China's MicroConstants
This article was originally published in Scrip
With China alone accounting for around half of the roughly 662,000 global deaths every year from hepatocellular carcinoma (HCC), novel drug candidates for the malignancy present an attractive prospect to licensees in the country.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.